GPX1 and Patent ductus arteriosus: In addition, there was no significant decrease in GPx1 expression in PDA cells pretreated with the proteasome inhibitor MG132, which blocks the catalytic activity of the proteasome (Fig. 3e, f), suggesting that GPx1 is subject to proteasomal degradation under glucose-deprived conditions.